DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 11 2022
Historique:
received: 12 01 2022
accepted: 27 10 2022
pubmed: 13 11 2022
medline: 16 11 2022
entrez: 12 11 2022
Statut: epublish

Résumé

Parkinson's disease is a progressive neurodegenerative disorder characterized by the preferential loss of tyrosine hydroxylase (TH)-expressing dopaminergic neurons in the substantia nigra. Although the abnormal accumulation and aggregation of α-synuclein have been implicated in the pathogenesis of Parkinson's disease, the underlying mechanisms remain largely elusive. Here, we found that TH converts Tyr136 in α-synuclein into dihydroxyphenylalanine (DOPA; Y136DOPA) through mass spectrometric analysis. Y136DOPA modification was clearly detected by a specific antibody in the dopaminergic neurons of α-synuclein-overexpressing mice as well as human α-synucleinopathies. Furthermore, dopanized α-synuclein tended to form oligomers rather than large fibril aggregates and significantly enhanced neurotoxicity. Our findings suggest that the dopanization of α-synuclein by TH may contribute to oligomer and/or seed formation causing neurodegeneration with the potential to shed light on the pathogenesis of Parkinson's disease.

Identifiants

pubmed: 36371400
doi: 10.1038/s41467-022-34555-4
pii: 10.1038/s41467-022-34555-4
pmc: PMC9653393
doi:

Substances chimiques

alpha-Synuclein 0
Tyrosine 3-Monooxygenase EC 1.14.16.2
Tyrosine 42HK56048U

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6880

Informations de copyright

© 2022. The Author(s).

Références

Science. 2000 Feb 18;287(5456):1265-9
pubmed: 10678833
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
Hum Mol Genet. 2008 Mar 15;17(6):906-17
pubmed: 18065497
Proteins. 2015 Apr;83(4):599-611
pubmed: 25663659
J Biol Chem. 2019 Dec 20;294(51):19683-19708
pubmed: 31672919
J Neurosci. 2006 Sep 6;26(36):9227-38
pubmed: 16957079
Brain Behav. 2012 Sep;2(5):595-605
pubmed: 23139905
Science. 2017 Dec 15;358(6369):1440-1443
pubmed: 29242346
Nat Rev Neurosci. 2013 Jan;14(1):38-48
pubmed: 23254192
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Biochemistry. 1991 Jul 2;30(26):6386-91
pubmed: 1675871
Acta Neuropathol. 2017 Dec;134(6):819-838
pubmed: 28803412
Brain. 2019 Jan 1;143(1):249-265
pubmed: 31816026
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Biochim Biophys Acta. 1988 Mar 23;953(2):142-56
pubmed: 2894860
Annu Rev Biochem. 2017 Jun 20;86:27-68
pubmed: 28498720
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
J Biol Chem. 2005 Mar 4;280(9):7800-7
pubmed: 15632170
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10813-8
pubmed: 12122208
Neurobiol Dis. 2015 Jul;79:81-99
pubmed: 25937088
J Neurosci. 2021 Mar 10;41(10):2264-2273
pubmed: 33483428
J Neurosci Methods. 2014 Feb 15;223:133-43
pubmed: 24361760
Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13176-13181
pubmed: 29180403
J Neurosci Methods. 2020 Dec 1;346:108914
pubmed: 32810474
Nat Genet. 1998 Feb;18(2):106-8
pubmed: 9462735
Lancet. 2004 Sep 25-Oct 1;364(9440):1167-9
pubmed: 15451224
Rapid Commun Mass Spectrom. 2020 May 15;34(9):e8734
pubmed: 32031718
Nat Struct Biol. 1997 Jul;4(7):578-85
pubmed: 9228951
Nat Commun. 2021 Mar 22;12(1):1814
pubmed: 33753734
J Neurosci. 2002 Apr 15;22(8):3090-9
pubmed: 11943812
Brain. 2014 May;137(Pt 5):1496-513
pubmed: 24662516
J Biol Chem. 2005 Mar 11;280(10):9595-603
pubmed: 15615727
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Nat Neurosci. 2017 May;20(5):681-689
pubmed: 28288128
Arch Biochem Biophys. 2011 Apr 1;508(1):1-12
pubmed: 21176768
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
FEBS Lett. 2014 Nov 3;588(21):3924-31
pubmed: 25240194
Science. 1996 Nov 15;274(5290):1197-9
pubmed: 8895469
Chem Pharm Bull (Tokyo). 2005 Sep;53(9):1167-70
pubmed: 16141589
J Biol Chem. 2016 Mar 25;291(13):6696-705
pubmed: 26851279
Proteins. 2010 Apr;78(5):1195-211
pubmed: 19938154
J Cell Sci. 2005 Aug 1;118(Pt 15):3523-30
pubmed: 16030137
Sci Rep. 2017 Nov 27;7(1):16386
pubmed: 29180624
Ann Neurol. 2004 Feb;55(2):164-73
pubmed: 14755719
Neuron. 2002 May 16;34(4):521-33
pubmed: 12062037
J Biol Chem. 2018 Dec 7;293(49):18914-18932
pubmed: 30327435
J Mol Biol. 2011 Aug 12;411(2):329-33
pubmed: 21689664
Science. 2010 Sep 24;329(5999):1663-7
pubmed: 20798282
J Neurochem. 2019 Sep;150(5):522-534
pubmed: 31254394
Nat Commun. 2014 May 29;5:3827
pubmed: 24871041
CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):395-409
pubmed: 22483313
J Clin Invest. 2009 Nov;119(11):3257-65
pubmed: 19855133
J Neurosci. 2004 Aug 18;24(33):7400-9
pubmed: 15317865
PLoS One. 2013;8(3):e49750
pubmed: 23505409
Q Rev Biophys. 2011 Nov;44(4):467-518
pubmed: 21729349
Acta Histochem. 2011 Jan;113(1):32-5
pubmed: 19683335
J Biol Chem. 2006 Oct 6;281(40):29739-52
pubmed: 16847063

Auteurs

Mingyue Jin (M)

Department of Genetic Disease Research, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, 545-8585, Japan.
Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guilin Medical University, Guilin, Guangxi, 541199, China.

Sakiko Matsumoto (S)

Department of Genetic Disease Research, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, 545-8585, Japan.

Takashi Ayaki (T)

Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.

Hodaka Yamakado (H)

Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.

Tomoyuki Taguchi (T)

Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.

Natsuko Togawa (N)

Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.

Ayumu Konno (A)

Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.

Hirokazu Hirai (H)

Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan.

Hiroshi Nakajima (H)

Division of Molecular Materials Science, Osaka Metropolitan University Graduate School of Science, Sumiyoshi-ku, Osaka, 558-8585, Japan.

Shoji Komai (S)

Department of Science and Technology, Nara Institute of Science Technology, Ikoma, Nara, 630-0192, Japan.

Ryuichi Ishida (R)

Department of Genetic Disease Research, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, 545-8585, Japan.

Syuhei Chiba (S)

Department of Genetic Disease Research, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, 545-8585, Japan.

Ryosuke Takahashi (R)

Department of Neurology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, 606-8507, Japan.

Toshifumi Takao (T)

Laboratory of Protein Profiling and Functional Proteomics, Osaka University Institute for Protein Research, Suita, Osaka, 565-0871, Japan.

Shinji Hirotsune (S)

Department of Genetic Disease Research, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, 545-8585, Japan. shinjih@omu.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH